STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss

June 1, 2026 updated by: Novo Nordisk A/S

Weight Maintenance in Adolescents With Obesity; Long-Term Treatment With Semaglutide s.c.2.4 mg Once-weekly

The study is testing how well semaglutide can help adolescents with excess body weight to lose weight and to maintain weight loss. All participants in the study will receive semaglutide as a weekly injection. The study medicine is injected with a thin needle in the stomach, thighs or upper arms. All participants will get semaglutide treatment for a minimum of 3 years.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Active, not recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
500

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Belgium
      • Brussels, Belgium, 1200
        • Cliniques Universitaires Saint-Luc
      • Brussels, Belgium, 1090
        • UZ Brussel - Universitair Ziekenhuis Brussel
      • Edegem, Belgium, 2650
        • UZA - Universitair Ziekenhuis Antwerpen
      • Leuven, Belgium, 3000
        • UZ Leuven
  • Canada
    • Alberta
      • Calgary, Alberta, Canada, T3B6A8
        • Alberta Children's Hospital
      • Edmonton, Alberta, Canada, T6G 2B7
        • Stollery Children's Hospital
    • British Columbia
      • Vancouver, British Columbia, Canada, V6H 3V4
        • BC Children's Hospital
    • Ontario
      • Markham, Ontario, Canada, L3P 7P3
        • Markham Stouffville Hosp
      • Toronto, Ontario, Canada, M5G 1X8
        • The Hospital for Sick Children
      • West Hamilton, Ontario, Canada, L8N 3Z5
        • McMaster Children's Hospital
    • Quebec
      • Montreal, Quebec, Canada, H4A 3J1
        • McGill Uni Health Ctre - Glen Site
      • Montreal, Quebec, Canada, H2J 1K1
        • Maison de Sante Prevention
  • Denmark
      • Aarhus, Denmark, 8200
        • Aarhus Universitetshospital, Steno Diabetes Center Aarhus
      • Gistrup, Denmark, 9260
        • Aalborg Universitetshospital - Børne og Ungeafdelingen
      • Holbæk, Denmark, 4300
        • Holbæk Sygehus - Børne- og Ungeafdelingen
  • France
      • Lille, France, 59037
        • Centre Hospitalier Universitaire de Lille-Hopital Jeanne de Flandre
      • Nice, France, 06200
        • Fondation Lenval Nice
      • Paris, France, 75012
        • Ap-Hp_Hopital Armand Trousseau
      • Rouen, France, 76031
        • Centre Hospitalier Universitaire de Rouen-Hopital Charles Nicolle
      • Toulouse, France, 31059
        • Hopital Des Enfants
  • Germany
      • Bochum, Germany, 44791
        • Kath. Klinikum Bochum gGmbH - Kinderklinik St. Josef-Hospital
      • Göttingen, Germany, 37075
        • Universitätsmedizin Göttingen - Klinik für Kinder-und Jugendmedizin
      • Göttingen, Germany, 37075
        • Uni-Med. Göttingen - Klinik für Kinder- und Jugendmedizin
      • Hanover, Germany, 30173
        • Hannoversche Kinderheilanstalt "Auf der Bult" - Diabeto-, Endokrino-, Gastroenterologie und Klinische Forschung
      • Hanover, Germany, 30173
        • Auf der Bult - Klinik für Diabetologie, Endokrinologie, Gastroenterologie und Klinische Forschung
      • Leipzig, Germany, 04103
        • Universitätsklinikum Leipzig - Klinik und Poliklinik für Kinder- und Jugendmedizin
      • Leipzig, Germany, 04103
        • Uniklinik Leipzig - Klinik und Poliklinik für Kinder- und Jugendmedizin
      • Ulm, Germany, 89075
        • Universitätsklinikum Ulm für Kinder- und Jugendmedizin
      • Ulm, Germany, 89075
        • Uniklinik Ulm - Dt. Zentrum für Kinder- und Jugendgesundheit (DZKJ)
  • Greece
      • Athens, Greece, 12462
        • U.G.H. "Attikon", Pediatric Endocrinology Outpatient Clinic
      • Goudi/Athens, Greece, 115-27
        • P & A Kyriakou Childrens' Hospital - Department of Endocrinology Growth and Development
      • Pátrai, Greece, 26504
        • General University of Patra - Paediatric Department
      • Thessaloniki, Greece, 546-42
        • 'Ippokrateio' General Hospital of Thessaloniki
      • Thessaloniki, Greece, 54642
        • Ippokrateio Gen Hosp of Thessaloniki, 1st Pediatric Clinic
  • Italy
      • Milan, Italy, 20154
        • Ospedale dei Bambini "Vittore Buzzi"
      • Roma, Italy, 00165
        • Ospedale Pediatrico Bambino Gesù
      • Trieste, Italy, 34137
        • IRCCS materno infantile Burlo Garofolo - Clinica Pediatrica
      • Verona, Italy, 37126
        • Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Civile Maggiore Borgo Trento
    • Tuscany
      • Florence, Tuscany, Italy, 50139
        • IRCCS Meyer Firenze
  • Mexico
      • Puebla City, Mexico, 72190
        • Consultorio de Endocrinología y Pediatría
    • Nuevo León
      • Monterrey, Nuevo León, Mexico, 64060
        • CHRISTUS - Latam Hub Excellence and Innovation Center
    • Tamaulipas
      • Ciudad Madero, Tamaulipas, Mexico, 89440
        • Centro de Estudios de Investigación Metabólicos y Cardio
  • Poland
      • Gdansk, Poland, 80-803
        • COPERNICUS Podmiot Leczniczy Sp. z o.o.
      • Katowice, Poland, 40-752
        • Górnośląskie Centrum Zdrowia Dziecka Im. Św. Jana Pawla II Samodzielny Publiczny Szpital Kliniczny Nr 6 SUM w Katowicach
      • Lodz, Poland, 92-213
        • UMED Clinical Trials sp. z o.o.
      • Rzeszów, Poland, 35-301
        • Kliniczny Szpital Wojewodzki nr 2 im. Sw. Jadwigi Krolowej w Rzeszowie
      • Stanisławow Pierwszy Nieporet, Poland, 05-126
        • ELIPSA - Elzbieta Lipska praktyka lekarska Osrodek Endokrynologii i Diabetologii Dzieciecej
      • Warsaw, Poland, 04-730
        • Instytut ''Pomnik - Centrum Zdrowia Dziecka''
      • Zabrze, Poland, 41-800
        • Samodzielny Publiczny Szpital Kliniczny Nr 1 im. Prof. Szyszko
    • Lower Silesian Voivodeship
      • Wroclaw, Lower Silesian Voivodeship, Poland, 50-368
        • Klinika Pediatrii, Endokrynologii, Diabetologii I chorób Metabolicznych, Uniwersyteckiego Szpitala Klinicznego in Wrocław
  • Saudi Arabia
      • Al Ahsa, Saudi Arabia, 36428
        • King Abdulaziz Hospital-Al Ahsa-National Guard
      • Jeddah, Saudi Arabia, 22384
        • National Guard Hospital - Jeddah
      • Riyadh, Saudi Arabia, 12372
        • King Khaled University Hospital,King Saud Univ. Med. City
      • Riyadh, Saudi Arabia, 12713
        • King Faisal Specialist Hospital & Research Centre, Riyadh
      • Riyadh, Saudi Arabia, 14611
        • National Guard Hospital_Riyadh
  • Sweden
      • Falun, Sweden, 791 37
        • Falu Lasarett - Barn- och ungdomsmedicinsk mottagning
      • Halmstad, Sweden, 30233
        • Hallands sjukhus Halmstad
      • Malmö, Sweden, 205 02
        • Skåne US Malmö - Barnöverviktsenheten
      • Sundsvall, Sweden, 85643
        • Sundsvalls sjukhus - Barn- och ungdomsmed mott
      • Uppsala, Sweden, 75185
        • Uppsala universitetssjukhus
  • United Kingdom
      • Birmingham, United Kingdom, B4 6NH
        • Birmingham Children's Hospital
      • Bristol, United Kingdom, BS2 8AE
        • University Hospitals Bristol & Weston NHS Foundation Trust
      • Leeds, United Kingdom, LS1 3EX
        • Leeds Children's Hospital
      • Liverpool, United Kingdom, L12 2AP
        • Alder Hey Children's Hospital
      • London, United Kingdom, NW1 1BU
        • University College Hospital - Paediatric Services
      • Sheffield, United Kingdom, S10 2TH
        • Sheffield Children's Hospital
      • Southampton, United Kingdom, SO16 6YD
        • Southampton General Hospital
  • United States
    • California
      • Escondido, California, United States, 92025
        • Neighborhood Healthcare
    • Florida
      • Orlando, Florida, United States, 32801
        • Clinical Neuroscience Solution
      • Tallahassee, Florida, United States, 32308
        • TMH Physician Partners Endo
    • Georgia
      • Atlanta, Georgia, United States, 30329
        • Children's Healthcare Atlanta
      • Columbus, Georgia, United States, 31904
        • Columbus Research Foundation
      • Snellville, Georgia, United States, 30078
        • Eastside Bariatric and Gen Surg
    • Idaho
      • Meridian, Idaho, United States, 83646
        • Solaris Clinical Research
    • Illinois
      • Chicago, Illinois, United States, 60602
        • Synexus Clinical Research US Inc.-Chicago
    • Indiana
      • Indianapolis, Indiana, United States, 46505
        • Indiana University Hospital
    • Iowa
      • Iowa City, Iowa, United States, 52242
        • University of Iowa Hospitals and Clinics
    • Louisiana
      • Baton Rouge, Louisiana, United States, 70808
        • Pennington Biom Res Ctr
    • Maryland
      • Baltimore, Maryland, United States, 21229
        • Barry J. Reiner, MD LLC
    • Minnesota
      • Minneapolis, Minnesota, United States, 55414
        • University of Minnesota
    • Mississippi
      • Madison, Mississippi, United States, 39110
        • Mississippi CTR for ADV MED
    • New York
      • Buffalo, New York, United States, 14203
        • UBMD Peds-Div of Endo/Diabetes
    • North Carolina
      • Raleigh, North Carolina, United States, 27610
        • WakeMed Childn Endo-Dbt_Raleig
    • North Dakota
      • Fargo, North Dakota, United States, 58104
        • Valley Weight Loss Clinic
    • Ohio
      • Columbus, Ohio, United States, 43213
        • Centricity Research - Ohio
      • Dayton, Ohio, United States, 45429
        • Primed Clinical Research
    • Pennsylvania
      • Pittsburgh, Pennsylvania, United States, 15224
        • UPMC Child Hosp-Pittsburgh
    • South Carolina
      • North Charleston, South Carolina, United States, 29405
        • Coastal Carolina Research Ctr
    • Tennessee
      • Memphis, Tennessee, United States, 38119
        • Clinical Neuroscience Solutions
    • Texas
      • San Antonio, Texas, United States, 78229
        • Clinical Trials of Texas Inc
      • San Antonio, Texas, United States, 78207-5209
        • Texas Diabetes Institute
    • Virginia
      • Newport News, Virginia, United States, 23606
        • Health Res of Hampton Roads
      • Richmond, Virginia, United States, 23298
        • Virginia Commonwealth Univ

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

No

Description

Inclusion criteria:

  • Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study:

    1. The parent(s) or legally acceptable representative (LAR) of the participant must sign and date the Informed Consent Form, according to local requirements
    2. The participant must sign and date the Child Assent Form or provide oral assent, according to local requirements
  • Age 12 to less than 15 years at the time of signing the informed consent
  • BMI greater than or equal to 95th percentile at screening
  • Body weight greater than 60 kg at screening

Exclusion criteria:

  • Prepubertal status (Tanner stage 1)
  • Treatment with any medication prescribed for the indication of obesity or weight management within 90 days before screening

  • Previous or planned (during the study period) obesity treatment with surgery or a weight loss device. However, the following are allowed:

    1. Liposuction and/or abdominoplasty, if performed more than 1 year prior to screening
    2. Adjustable gastric banding, if the band has been removed more than 1 year prior to screening
    3. Intragastric balloon, if the balloon has been removed more than 1 year prior to screening
    4. Duodenal-jejunal bypass liner (e.g., Endobarrier), if the sleeve has been removed more than 1 year prior to screening
  • Endocrine, hypothalamic, or syndromic obesity
  • History of type 1 or type 2 diabetes mellitus

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Semaglutide
2.4mg or maximum tolerated dose(MTD) injected subcutaneously (under the skin, s.c) once weekly
Drug: Semaglutide
Participants will receive semaglutide s.c(under the skin) once weekly.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Maintenance of Body Mass Index (BMI) below obesity threshold
Time Frame: From 1.5 years to 3 years
Measures as count of participants
From 1.5 years to 3 years

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Maintenance of improved Body Mass Index (BMI) category
Time Frame: From 1.5 years to 3 years and end of continued treatment phase (up to 6 years)
Measured as count of participants
From 1.5 years to 3 years and end of continued treatment phase (up to 6 years)
Tapering to zero dose
Time Frame: From 1.5 years to 3 years
Measured as count of participants
From 1.5 years to 3 years
Time/dose steps before ending dose tapering
Time Frame: From 1.5 years to 3 years
Measured in weeks, count of dose steps
From 1.5 years to 3 years
Achieving Body Mass Index (BMI) below obesity threshold
Time Frame: From baseline (day 0) to 1.5, 3 years and end of continued treatment phase (up to 6 years)
Measured as count of participants
From baseline (day 0) to 1.5, 3 years and end of continued treatment phase (up to 6 years)
Achieving any improvement in Body Mass Index (BMI) category
Time Frame: From baseline (day 0) to 1.5, 3 years, and end of continued treatment phase (up to 6 years)
Measured as count of participants
From baseline (day 0) to 1.5, 3 years, and end of continued treatment phase (up to 6 years)
Change in Body Mass Index (BMI)
Time Frame: From baseline (day 0) to 1.5 and 3 years
Measured in percentage (%)
From baseline (day 0) to 1.5 and 3 years
Body Mass Index (BMI) percentage of the 95th percentile
Time Frame: From baseline (day 0) to 1.5 and 3 years
Measured in percentage (%)
From baseline (day 0) to 1.5 and 3 years
Change in Body Mass Index Standard Deviation Score (BMI SDS)
Time Frame: From baseline (day 0) to 1.5 and 3 years
Unitless
From baseline (day 0) to 1.5 and 3 years
Change in waist-to-height ratio (waist [cm]/ height [cm])
Time Frame: From baseline (day 0) to 1.5 and 3 years
Unitless
From baseline (day 0) to 1.5 and 3 years
Change in waist circumference
Time Frame: From baseline (day 0) to 1.5 and 3 years
Measured in centimeters (cm)
From baseline (day 0) to 1.5 and 3 years
Change in HbA1c
Time Frame: From baseline (day 0) to 1.5, 3 years and end of continued treatment phase (up to 6 years)
Measured in percentage (%) points
From baseline (day 0) to 1.5, 3 years and end of continued treatment phase (up to 6 years)
Change in fasting plasma glucose
Time Frame: From baseline (day 0) to 1.5, 3 years and end of continued treatment phase (up to 6 years)
Measured in millimol per liter (mmol/L), milligram per deciliter (mg/dL)
From baseline (day 0) to 1.5, 3 years and end of continued treatment phase (up to 6 years)
Change in fasting insulin and Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)
Time Frame: From baseline (day 0) to 1.5, 3 years and end of continued treatment phase (up to 6 years)
Measured in percentage (%)
From baseline (day 0) to 1.5, 3 years and end of continued treatment phase (up to 6 years)
Change in high sensitivity C-reactive protein (hsCRP)
Time Frame: From baseline (day 0) to 1.5, 3 years and end of continued treatment phase (up to 6 years)
Measured in percentage (%)
From baseline (day 0) to 1.5, 3 years and end of continued treatment phase (up to 6 years)
Change in alanine aminotransferase (ALT), total cholesterol, high density lipoprotein (HDL), low density lipoprotein (LDL), very low-density lipoprotein (VLDL) and triglycerides
Time Frame: From baseline (day 0) to 1.5, 3 years and end of continued treatment phase (up to 6 years)
Measured in percentage (%)
From baseline (day 0) to 1.5, 3 years and end of continued treatment phase (up to 6 years)
Change in systolic and diastolic blood pressure
Time Frame: From baseline (day 0) to 1.5, 3 years and end of continued treatment phase (up to 6 years)
Measured in millimetres of mercury (mmHg)
From baseline (day 0) to 1.5, 3 years and end of continued treatment phase (up to 6 years)
Change in fat mass, by dual X-ray absorptiometry (DXA) relative to total body mass
Time Frame: From baseline (day 0) to 1.5 and 3 years
Measured in percentage (%) points
From baseline (day 0) to 1.5 and 3 years
Change in lean body mass, by dual X-ray absorptiometry (DXA) relative to total body mass
Time Frame: From baseline (day 0) to 1.5 and 3 years
Measured in percentage (%) points
From baseline (day 0) to 1.5 and 3 years
Serious Adverse Event (SAE)
Time Frame: From baseline (day 0) to 1.5 years, from 1.5 to 3 years, and from 3 years to end of continued treatment phase (up to 6 years)
Count
From baseline (day 0) to 1.5 years, from 1.5 to 3 years, and from 3 years to end of continued treatment phase (up to 6 years)
Relative change in visceral fat mass, by dual X-ray absorptiometry (DXA)
Time Frame: From baseline (day 0) to 1.5 and 3 years
Measured in percentage (%)
From baseline (day 0) to 1.5 and 3 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Novo Nordisk A/S

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: Clinical Transparency (dept. 2834), Novo Nordisk A/S

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
September 17, 2024

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
November 15, 2028

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
November 15, 2031

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
August 22, 2024

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 22, 2024

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
August 26, 2024

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
June 2, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 1, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
June 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • NN9536-7752
  • U1111-1295-4799 (Other Identifier: World Health Organisation (WHO))
  • 2023-508055-40 (Other Identifier: European Medical Agency (EMA))

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Obesity

Clinical Trials on Semaglutide

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings